Testing UTAA17 for advanced multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new treatment called UTAA17 that targets a protein on myeloma cells. It may be an option for people whose multiple myeloma has not responded to several prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have multiple myeloma that came back or didn't respond to at least 3 treatments.
- Your cancer cells have a specific marker called BCMA on their surface.
- You are in fairly good health, able to do daily activities, and have a life expectancy of at least 12 weeks.
- Your major organs (heart, lungs, liver, kidneys) and blood counts are working well enough, as shown by recent tests.
- You have not had certain infections (like hepatitis B or C, HIV, or active viral infections) or serious heart problems in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
This trial tests two drugs, elranatamab and isatuximab, given together to people whose multiple myeloma has come back or stopped responding to earlier treatments. The goal is to see if the combination can shrink or control the cancer where other therapies have not worked well.
This trial tests an experimental therapy called CT071 for people with newly diagnosed, high-risk multiple myeloma. It aims to see if this treatment can help control the disease in people who have certain aggressive features.
This study tests an experimental drug called RN9101 for people with multiple myeloma that has returned or stopped responding to other treatments. The drug targets a protein called BCMA found on myeloma cells, and the goal is to see if it is safe and can help control the disease.
This trial tests a new drug called QI-019A for people whose multiple myeloma has returned or stopped responding to at least two prior treatments. The goal is to see if it is safe and if it can help control the disease.
This trial tests a new experimental drug called CM336 for people with multiple myeloma that has come back or stopped responding to standard treatments. The drug may work by helping your immune system attack and destroy myeloma cells. If you join, you will receive the study treatment and be closely monitored to see how well it works and how safe it is.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.